Basilea Pharmaceutica has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera or ceftobiprole in the United States.
Basilea will receive a $4 million upfront payment and tiered royalties on net sales in the high-teens to mid-twenties percentage range. Basilea will be eligible to receive sales milestones of up to $223 million. Also, Innoviva Specialty Therapeutics will purchase its demand of Zevtera drug product from Basilea.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.